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Stroke is an important health issue corresponding to the second cause of mortality and first cause of severe disability with no
effective treatments after the first hours of onset. Regenerative approaches such as cell therapy provide an increase in endogenous
brain structural plasticity but they are not enough to promote a complete recovery. Tissue engineering has recently aroused a major
interesting development of biomaterials for use into the central nervous system. Many biomaterials have been engineered based
on natural compounds, synthetic compounds, or a mix of both with the aim of providing polymers with specific properties. The
mechanical properties of biomaterials can be exquisitely regulated forming polymers with different stiffness, modifiable physical
state that polymerizes in situ, or small particles encapsulating cells or growth factors. The choice of biomaterial compounds should
be adapted for the different applications, structure target, and delay of administration. Biocompatibilities with embedded cells and
with the host tissue and biodegradation rate must be considerate. In this paper, we review the different applications of biomaterials
combinedwith cell therapy in ischemic stroke andwe explore specific features such as choice of biomaterial compounds andphysical
and mechanical properties concerning the recent studies in experimental stroke.
1. Introduction
The stroke is a major public health issue in the world
due to aging populations and the socioeconomic burden of
neurovascular disorders. It corresponds to the one of the
leading causes of death and severe disability in adults world-
wide. Ischemic stroke is the most common type of stroke
corresponding to 85% of all strokes [1]. Pathophysiology of
ischemic stroke involves a complex and dynamic process
which is not limited to neurons but involves all brain cells and
extracellular matrix (ECM) in a “glioneurovascular niche”
that interacts with the peripheral immune system. Stroke
patients could benefit from reperfusion therapies up to 6 h
after ischemic stroke onset [2]. After these first hours, there is
no effective treatment available besides rehabilitation [3].
Development of innovating therapies using stem cells or
trophic factors can enhance brain remodeling; this process is
crucial and success requires a pathophysiological viewpoint
[4]. These approaches also have the advantage of action
over an extended therapeutic time-window after stroke and
thereby might be effective in more patients than those
helped by current acute strategies such as thrombolysis and
thrombectomy. Cell-based therapy has been proposed as a
potential source of new cells to replace lost cells due to central
nervous system injury, aswell as a source of trophicmolecules
to minimize damage and promote recovery [5, 6].
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Figure 1: Schematic illustration of different biomaterial applications on ischemic brain. (a) Solid brain scaffolds for surface application and
gradual liberation of cells, drugs, or growth factors. (b) Injectable hydrogel, in liquid phase with an in situ gelation. (c) Microspheres for
gradual intracerebral delivery.
Stem/progenitor cell transplantation improves recovery
after stroke in rodent models [7]. Nevertheless, there are two
main limits concerning clinical translation in cell transplan-
tation in stroke [8].
Firstly, when the stem/progenitor cells are systemically
administrated, this requires the administration of a high
number of cells and only a few amounts of cells achieve
the brain [9]. An alternative way is the intracerebral (IC)
administration of cells directly into the brain parenchyma
and/or into the lesion cavity [10] (Figure 1). This location is
a compartmentalized area of lost tissue that has undergone
necrosis and can allow a large volume injection, and it is
directly adjacent to peri-infarct zone [11], site of greatest
neuroplasticity after stroke [12].
The second point concerning cell administration is the
important cell death observed after IC graft. After stroke,
within the infarct cavity, a very important loss of ECM in
addition to neuronal and glial cell loss is noted. This cavity
is filled by extracellular fluid and proteins from leakage
of plasma proteins [13]. This damaged area is a hostile
environment for cell transplantations resulting in a severe loss
of grafted cells [14, 15].
Recent advances in tissue engineering have produced
applications that may provide solutions to the problem of
Stem Cells International 3
transplanted cell death and damage associated with the
transplant [11]. Biopolymer hydrogels have been projected to
promote cell survival and engraftment (Figure 1).
Currently, biomaterials researchers are seeking to opti-
mize injectable hydrogels by combining cell seeding with
the incorporation of growth factors or tracers. The use of
biomaterials to improve benefit of cell therapy after stroke
must be carefully investigated in experimental studies prior
to transferring this promising procedure to clinical trials.
In this paper, we aim to review the different applications
of biomaterials after ischemic brain lesion and to explore
specific features such as the choice of biomaterial compounds,
physical and mechanical properties, biocompatibilities, and
degradation regarding recent studies in experimental stroke
(Table 1).
Stem Cell in Stroke Repair. The benefits of exogenous cell-
based strategies include their potential to rescue dam-
aged brain tissue by simultaneously promoting endogenous
neuroprotection and neural repair (including neurogenesis,
angiogenesis, oligodendrogliogenesis, axonal sprouting, and
synaptogenesis) [6]. Additionally, these cells could act in
synergywith endogenous stem cells.The different cell sources
and types were recently reviewed by Jendelova´ et al. [16].
Currently, we distinguish two main strategies of cell
therapy: (1) a paracrine trophic support using “peripheral”
stem or stromal cells and (2) a direct neural replacement
using neural stem/progenitor cells or mature cells such as
neurons. The route, dose, and timing for cell transplantation
after stroke are still debated, depending on the chosen cell
product and the expected therapeutic effect.
Direct replacement of injured neurons (“homotopic”
repair) has been suggested after neural stem cells (NSC) IC
administration [17] or intra-arterial (IA) injection [18].These
results were demonstrated by using induced pluripotent stem
cells (iPSC) derived neurons [19], bone marrow stromal
cells (BMSCs) [20], or embryonic stem cells (ESC) derived
mesenchymal stem cells (MSC) injections [21]. However,
only a few grafted cells can be expected to express neuronal
markers, and long-term graft survival is relatively poor [22–
26]. Moreover, despite possible integration of grafted NSCs
[27–29] into the host circuitry, functional recovery occurs,
too early to be caused by newly formed neurons and synapses.
The effects of cell therapies on poststroke vasculoge-
nesis and angiogenesis seem to be crucial. IC injection
of endothelial cells can improve vasculogenesis linked to
neurogenesis via vascular endothelial growth factor (VEGF)
release mechanisms [30]. Proangiogenic effects were also
observed early after MSC injection contributing to VEGF-
induced angiogenesis [31], after injection of NSC [32, 33],
endothelial progenitor (EP) [34], or cord-bloodmononuclear
cells CD34+ [35]. Moreover, EP, MSC, or NSC can also
facilitate protection or restoration of the blood-brain barrier
after stroke [33, 36, 37].
Another important effect of cell therapy is enhancement
of glial remodeling and limitations in anterograde degenera-
tion [38–40]. For example, intravenous (IV) injection ofMSC
has beneficial effects on both poststroke glial remodeling and
axonal remyelination [41]. It also increases glial cell-derived
neurotrophic factor (GDNF) levels, creating a hospitable
environment for neural repair and neuroblastmigration from
the subventricular zone (SVZ) [42].
Additionally, cell therapies can limit host cell death
through antiapoptotic and immunomodulatorymechanisms.
Although MSCs are known to attenuate microglia and
leukocyte inflammatory responses after stroke [43–45], some
immunomodulatory properties were also observed for cord-
blood cells [46] or NSC [47, 48], which can both influence
splenic inflammatory responses after stroke [49].
2. Biomaterials as Cell Scaffold to
Enhance Cell Graft
An important cell death is reported after IC graft into
the damaged area [14, 15]. The use of “carrier” scaffolds is
particularly relevant for injections into the stroke cavity at
a chronic stage, avoiding a deleterious injection into the
adjacent brain tissue where important recovery processes
may be underway.
Enhancing the graft survival after IC injection is the
common aim of several ongoing experimental strategies.
Advances in regenerativemedicine are increasingly providing
new opportunities to repair damaged tissue by using bio-
materials to enhance cell graft. Biomaterials are materials
specially developed for use in tissues with the minimum
of biological response to the foreign body. Furthermore,
biomaterial seems to improve graft cell survival, proliferation,
migration, and differentiation, protecting grafted cells from
immune response and thus improving cell therapy effects.
A study using matrix gel scaffolding associated with
human ESC neuronal precursor cells (NPCs) administrated
3 weeks after an experimental ischemic stroke in rats demon-
strated beneficial effects induced by biomaterial coadminis-
tration. The effects include cell survival and neuronal differ-
entiation, reduction of infarct volume, and improvement of
functional outcome [50].
Biomaterials improve cell survival even if these cells
are administrated in the intact brain adjacent to the lesion.
A study using a thermoreversible gelation polymer (TGP)
as scaffold in MSCs transplantation demonstrated that the
association of MSC-TGP significantly improved cell survival
[51].The fate of transplantedMSCwas examined 8weeks after
transplantation with immunohistochemistry.Themajority of
cells were positive for both NeuN and MAP2 [51].
Zhong et al. tested the effects of a Hyaluronan-Heparin-
Collagen based hydrogel in cell protection in vitro [11].
Stem cell survival was tested under conditions of growth
factor and nutritional support and under conditions of
stress induced by growth factor and nutrition withdrawal to
mimic the initial transplant state. In stem cell cultures with
nutrient and growth factor support, the hydrogel modestly
but significantly increased survival. In stem cell cultures
without such support, the hydrogel substantially increased
the survival [11]. Furthermore, they demonstrated that this
hydrogel was able to improve the survival of NPCs into the
brain cavity after stroke. Additionally, the authors reported
a reduction of inflammatory cells infiltration into the graft.
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model Biomaterial Outcomes References
hRecombinant
osteopontin Rats tMCAO Gelatin type A microspheres
↓ of infarct volume neurological
deficits
Jin et al. 2014
[122]
rBMSCs Rats pMCAO N-Isopropyl- acrylamidepolymer sheets Improvement of motor function








PLGA nanoparticles dispersed in
a (HAMC) hydrogel




hNSC Rats tMCAO VEGF-PLGA microparticles Neovascularization, angiogenesis Bible et al.2012 [123]
iPS-NPCs Mice corticalphotothrombotic HA, acrylate ↑ of differentiation to neuroblast
Lam et al.
2014 [95]
hNSC Rats tMCAO Xenogeneic (ECM) bioscaffold Formation of de novo tissue Bible et al.2012 [121]
ONO-1301 Rats tMCAO Subcutaneous (PLGA)microspheres
Neuroprotection and ↓ side
effects compared to OA
Hazekawa et
al. 2012 [81]





PEG microparticles dispersed in
a (HAMC) hydrogel ↑ neural stem/progenitor cells
Cooke et al.
2011 [125]
NSC Rats tMCAO Collagen type I matrix ↑ synapses and functionalrecovery
Yu et al. 2010
[57]




MCAo p or t, permanent or transientmiddle cerebral artery occlusion; BMSCs, bonemarrow stromal cells; EGF, epidermal growth factor; EPO, erythropoietin;
SC, stem cells; PEG, polyethylene glycol; HAMC, hyaluronanmethylcellulose; h, human; NSC, neural stem cells; VEGF, vascular endothelial growth factor, iPS,
induced pluripotent stem; HA, hyaluronic acid; NPCs, neural pluripotent cells; PLGA, poly lactic-co-glycolic acid; OA, oral administration; HMGB1, high-
mobility group box 1 protein; ECM, extracellular matrix.
Active microglia/macrophages infiltrating the cell engraft-
ment were significantly decreased with hydrogel [11].
Such as described below (see“Interest of Biomaterials in
Cell Therapies”), the inflammatory response is an important
step of healing process. Nevertheless, it is recognized that a
reduced inflammatory response can result in amore favorable
outcome.
Biomaterials alone are able tomodulate the inflammatory
response. In a cortical brain damage model, a three percent
HA gel was coated onto the lesion for the experimental
groups and normal saline solutions for the control groups.
The results from immunohistological analysis put in evidence
a significant reduction of the number of GFAP+ cells [52].
The ultimate goal of stroke treatment is the functional
recovery. Identifying behavioral deficits in animal models
of stroke is essential for potential translational applications
[53]. As we noted, regenerative approaches such as cell
therapy and administration of trophic factors provide an
increase in endogenous brain structural plasticity and motor
remapping after ischemia [54]. The use of biomaterials
may enhance these functional effects. Emerich et al. have
demonstrated that alginate hydrogel used as implant for sus-
tained release of VEGF promotes functional and structural
protection from ischemic damage after transient ischemia
[55]. The group treated with VEGF-Hydrogel had an impor-
tant decrease (about 80%) in lesion volume evaluated by
2,3,5-triphenyltetrazolium chloride (TTC) staining. Behav-
ioral analysis using motor asymmetry and neurologic scores
demonstrated that recovery is improved by the association
of hydrogel-VEGF compared to VEGF alone [55]. Similarly,
Guan et al. demonstrated that human MSCs transplanted
with collagen scaffolds in a model of brain injury present bet-
ter outcomes compared toMSC alone [56]. Collagen scaffolds
increased the retention of MSC in the lesion site and limited
its distribution at the transplanted region resulting in better
functional recovery during 4weeks after transplantation [56].
Another study assessed the combination of NSC and collagen
type-I administrated 24 hours after stroke and showed an
improvement of the structural and functional recovery [57].
In this study, rats were submitted to a transient ischemia
and received a graft of a brain scaffold of collagen type-I
seeded withNSC.The evaluation bymicroscopy showed that,
30 days after transplantation, NSC-collagen group presented
new synapses and better functional recovery, while at this
time point collagen has been completely degraded [57].
2.1. Interest of Biomaterials in Cell Therapies. Some minutes
after blood flow interruption and energetic deprivation, a
cascade of cellular and molecular mechanisms are activated
resulting in cell death.
Inflammation is initiated by necrosis and tissue injury
through the recognition of damage associated molecular
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patterns [58]. The process of activation of inflammatory
response is currently incompletely understood [59]. Inflam-
mation subserves a number of biological functions and can
have both positive and negative consequences [60]. This
process is necessary to remove necrotic and apoptotic cells
and cleaved extracellular matrix molecules and to initiate
angiogenesis and tissue repair [61]. However, exacerbates and
chronic inflammation lead to the formation of inhospitable
environment for regeneration and cell grafting, resulting in
further cell death.
The ischemic lesion promotes changes in extracellular
environment such as ECM.The ECM is a three-dimensional,
noncellular structure composed of collagens, elastin, proteo-
glycans (including hyaluronan), and noncollagenous glyco-
proteins [62] in healthy conditions. ECM macromolecules
are bioactive and modulate cellular events such as adhesion,
migration, proliferation, differentiation, and survival [63].
During brain ischemia, the basement membranes of blood-
brain barrier are degraded and new ECM proteins are
deposited in brain parenchyma, either by secretion from
activated glia or by leakage of plasma proteins, such as
fibrinogen [64]. The significance and consequences of these
changes may vary with the time point after injury [13].
Remodeling and repair of brain parenchyma are influ-
enced by ECM composition. Stroke induces alterations in
ECM such as increase of proteoglycans [65], inhibition of
neurite outgrowth by astrocytic activation [66], and upreg-
ulation of matrix-metalloproteinases (MMPs) [62]. These
mechanisms can contribute negatively to endogenous remod-
eling and to the host response to cell therapy.
To enhance structural and functional recovery after
stroke, biomaterials protecting grafted cells and/or support-
ing repair processes such as ECM substitute are currently
in development and could be a promising neurorestorative
approach.
3. Biomaterials Components
Biomaterials are based on natural or on synthetic compounds
used alone or in mixtures, providing a polymer with different
properties [67]. The choice of biomaterial is of importance
because it can influence biomaterial effectiveness and the
response of host tissue. Natural polymers such as hyaluronan,
chitosan, and collagen are advantageous because they have
already been used in clinical applications as injectable hydro-
gels such as lubrifiants, wound sealants, viscosupplements, or
filling agents in esthetic medicine [68, 69].
On the other hand, synthetic hydrogels can be engineered
to more accurately mimic the physical and mechanical
characteristics of ECM [70]. The advantage of synthetic
biomaterials is the ability to tightly control the polymeriza-
tion, degradation, and biocompatibility of hydrogel. Synthetic
hydrogels are better chemically defined and in most cases are
biologically inert, reducing potential immune reaction into
the brain [70]. In this section, we explore some components
used in recent studies in experimental stroke.
3.1. Chitosan. Biomaterial can be produced from chitosan, a
natural polysaccharide produced by deacetylation of chitin
from crustacean shells [71]. Chitosan-based biomaterials
have been used in different applications such as corneal
wound healing [72], peripheral nerve injury [73], and
mechanical brain injury [74]. In a recent study, chitosan
hydrogel coadministrated with ESC-derived endothelial cells
showed a positive effect by presenting a high cell survival
and minimal cytotoxicity in vitro [75]. When this chitosan-
based hydrogel encapsulating mixed adult and endothelial
cells and containing VEGF was implanted into a mouse
model of hindlimb ischemia, it induced neovascularization
through vasculogenesis and angiogenesis. It also led to
recovery of blood flow in ischemic hindlimbs [75]. Ding et
al. have demonstrated a most pronounced neuroprotective
effect mediated by acetyl-11-keto-𝛽-boswellic acid (AKBA)
loaded in O-carboxymethyl chitosan nanoparticles (NPs)
when compared to the AKBA only in a rat model of
ischemic stroke [76].The combinationAKBA+NPs promoted
a functional improvement by reducing infarct volume and
apoptosis [76]. However, chitosan-based biomaterials present
some disadvantages such as a fast biodegradation in situ.
Additionally, the compatibility of chitosan with physiological
medium depends on the preparation method. Residual pro-
teins could indeed cause allergic reactions [71].
3.2. Hyaluronic Acid (HA). Another promising material is
HA, an abundant glycosaminoglycan in the brain ECM
[13, 62, 63]. HA is a linear polymer composed of the
repeating disaccharide unit of D-glucuronic acid and N-
acetyl-D-glucosamine. This polysaccharide plays a key role
in many biological processes such as stabilizing the ECM,
regulating cell adhesion and motility, and mediating cell
proliferation and differentiation [77]. Liang et al. reported an
increase in engrafted cells’ survival and proliferation of three
different cell lines (C17.2 cells, human neural progenitor cells
(ReNcells), and human glial-restricted precursors) into aHA-
gelatin-polyethylene glycol diacrylate (PEGDA) gel, although
a mild inflammatory response towards the implanted hydro-
gel was observed [8]. As an example, we report here that the
same HA hydrogel can be used for MSC transplantation after
experimental stroke (Figure 2).
3.3. Poly(Latic-co-glycolic Acid) (PLGA). PLGA is one of
most commonly used biodegradable synthetic polymers for
three-dimensional (3D) scaffolds in tissue engineering [78].
The advantage of synthetic polymers is a high control of
degradation rate and mechanical properties [79]. PLGA is
biocompatible and has been investigated to increase cell
survival. NSCs grafted into PLGA slices of 2mm depth
were viable after 14 days of culture [80]. PLGA can be
used to produce microspheres for a gradual delivery of
cells or drugs [81–83]. Bible et al. optimized the conditions
for cell attachment in order to preserve the MHP36 cell
line properties in PLGA microspheres [84]. In this experi-
ment, 100–200𝜇m PLGA microparticles that were modified
with poly(allylamine) via plasma polymerization of ally-
lamine and further coated with plasma-derived fibronectin
were administrated into the lesion cavity (two weeks after
stroke). They demonstrated a primitive de novo tissue
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Figure 2: Different experimental steps for intracerebral graft of cell-biomaterial after stroke. Scale bar = 100 𝜇m. (a) In vitro biocompatibility:
after mixing human mesenchymal stem cells (MSC) within hyaluronic acid (HA) hydrogel (Hystem HP, Sigma: hyaluronan+polyethylene
glycol diacrylate),MSC survived into the gel during several days in culture (A1) without cell death (A2, propidium iodide cell dead assay). Cell
survival and spreading into theHA gel were assessed in one-week culture (A3) using confocalmicroscopy and confocalmicroscopy stacks and
viable cell labelling (A4 and A5, Cell Tracker Green CMFDA, Life). (b) Intracerebral transplantation: one week after experimental ischemic
stroke in rat, magnetic resonance imaging was used to determine the injection site into the stroke cavity near plastic areas surrounding the
lesion (B1). Coordinates for stereotactic injectionwere defined using anatomic atlas (Watson-Paxinos) (B2). By histology, the stereotactic tract
can bemacroscopically observed (B3, crysostat section). (c) In vivo biocompatibility and effects: ex vivo brain immunohistology demonstrated
cell survival into the graft site such as humanMSC identification in stroke lesion (C1, human-specificmonoclonal antibody to nuclear antigen,
MAB1281, 1/1,000, Chemicon) without cell migration in contralateral hemisphere (C2). Additional experiments must be done to assess long-
term cell differentiations and host integration, hydrogel biodegradation, local inflammatory response, and behavior recovery effects.
formation within 7 days [84]. Another interesting study
using PLGA microspheres showed that a single subcuta-
neous administration of ONO-1301 (a long-acting prosta-
cyclin agonist) in PLGA microspheres was able to improve
poststroke recovery, edema, and infarct volume in rats
[81].
There are some concerns that PLGA degrades into acidic
by-products within the brain that may exacerbate inflam-
mation and secondary damage after brain injuries [79].
The less explored poly-𝜀-caprolactone (PCL) polymers might
be a safer alternative. PCL induced a lower inflammatory
response than PLGA, as demonstrated by lower activated
macrophages and glial fibrillary acidic protein (GFAP)
expression [85].
4. Mechanical and Physical Properties
Biomaterials can be produced using various types of poly-
merization and take on distinct forms such as solid scaffolds,
hydrogels, or micro/nanoparticles. The choice of biomaterial
stiffness depends on the administration site target (brain
surface or parenchyma), delay of release intended (gradual or
immediate), and the therapeutic goal (Figure 1).
Solid scaffolds require surgery to implant and thus
are more suitable for surface application [86, 87]. In situ
gelling hydrogels and particles can typically be delivered in
a minimally invasive manner using a syringe without the
need of open surgery [58]. Hydrogel micro/nanoparticles
are also suited for protein, gene, and drug delivery [76, 88,
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89]. Hydrogels can be used to graft cells and to provide a
microenvironment that can be tuned, promoting cell survival
and improving function [8, 11, 57] (Figure 1).
4.1. Brain Scaffolds. In a recent study, Hwang et al. used
a model of corticectomy to monitor in a noninvasive way
by bioluminescence the behavior of stem cells embedded
within poly-L-lactic acid (PLLA) scaffold [86]. Human NSCs
expressing enhanced firefly luciferase were implanted into
the ablated area with or without a PLLA scaffold. They have
demonstrated that NSC survived over 14 days compared with
8 days for the nonencapsulated cells [86]. The mechanical
strength or stiffness of a hydrogel is named compressive
modulus measured in kPa. Solid scaffolds can be projected to
present compressive moduli that stimulate cell survival and
proliferation [90].
4.2. Injectable Hydrogels. Hydrogels are 3D cross-linked net-
works of water-soluble polymers [91]. Hydrogel polymers
can absorb a high water content up to 99%, due to their
hydrophilic nature [70], and can be engineered in a vari-
ety of physical forms, including a liquid state for in situ
cross-linking [8]. They have excellent nutrient and oxygen
permeability, allowing cell survival in the scaffold [92]. The
most important advantage of this kind of biomaterial is that
hydrogels form in situ [79], allowing an administration with
a minimal invasiveness by injection [8, 11, 68]. The cross-
linking process can be induced by temperature [93], pH [94],
or addition of a synthetic cross-linker such as PEGDA for
HA hydrogel. Besides, hydrogels possess elastic properties
that are similar to those of brain tissue. Hydrogels injected
in liquid phase usually present low compressive moduli after
polymerization, which promotes a stem cell differentiation
toward neural lineages [90].
Lam et al. assessed the effect of cell therapy by admin-
istrating neural progenitor cells derived from iPSC (iPSC-
NPC) into the infarct cavity of mice submitted to a cortical
photothrombotic stroke. iPSC-NPCs were encapsulated in
a HA hydrogel matrix or in PBS [95]. The combination
(hydrogel + iPSC-NPC) was able to promote differentiation
of the neural progenitor cells to neuroblasts. Despite this
good result, it did not increase cell survival one week
after transplantation [95]. The hydrogels used in this study
were synthesized to contain the adhesion peptide and were
cross-linked with either matrix-metalloproteinase (MMP)
degradable peptides or non-MMP degradable peptides. The
hydrogel was specifically engineered to have a compressive
modulus of ∼3 kPa because that is the approximate stiffness
of the brain [96]. In a recent study, Massensini et al. assessed
rheological properties and gelation at body temperature
of a biological hydrogel produced from porcine urinary
bladder ECM [97]. They performed an efficient MRI-guided
injection with drainage of fluid from the cavity to assess
in situ hydrogel formation and ECM retention at different
concentrations. The concentrations superior than 3mg/mL
polymerized within stroke cavity, whereas lower concentra-
tions remained in liquid phase permeating the peri-infarct
area.
A downside to hydrogels is that cell migration and
outgrowth are often poor due to its weak mechanical struc-
ture [79]. Moreover, biodegradation rate is hard to control
[98] and must be carefully investigated in the future (see
Section 5).
4.3. Microencapsulation. Biomaterials can also be used to
encapsulate molecules, cells, cell aggregates, or drugs with
the aim of promoting a gradual liberation [88, 99] or graft
protection. Molecules or cells encapsulation can be automa-
tized to provide a large number of implantable “active” cap-
sules. This could be an alternative to intracerebroventricular
injection through the catheter/osmotic minipump systems.
This strategy provides a gradual release and a sufficient
penetration of growth factors in brain tissue [99]. Nakaguchi
et al. have demonstrated an increase in the endogenous
neurogenesis in the SVZ of adult mice induced by IC admin-
istration of growth factors: insulin-like grow factor 1 and
hepatocyte growth factor encapsulated into gelatin hydrogel
microspheres [100]. For NSC grafting, Skop et al. optimized
multifunctional and biocompatible chitosan-based films and
microspheres. Heparin was covalently cross-linked to the
chitosan scaffolds which bound fibroblast growth factor-2
(FGF-2) and sustain survival and growth of NSC [101].
4.4. Neural Networks as Potential Strategy. In general way, cell
replacement strategies do not take account of the complexity
of the brain. Indeed, the cerebral abilities are linked to
highly complex connections established between specialized
neuroanatomical regions. Replacing lost neurons and extra-
cellular environment does not warrant the restoration of this
complex network of axonal tracts. Focusing on this question,
alternative biomaterials have been developed with the aim
to restore long-distance axonal connections. Replacing lost
neurons and extracellular environment does not warrant
the restoration of this complex network of axonal tracts.
Focusing on this question, alternative biomaterials have been
developed with the aim of restoring long-distance axonal
connections.
A recent strategy in neural tissue engineering involves
the development and application of “living scaffolds,” which
are defined as constructs with a controlled, often heteroge-
neous, and anisotropic 3D cell architecture and biomaterial
composition [102]. This living cellular-biomaterial scaffold
presents a new form to implant biomaterials and cells. These
living scaffolds are able to orientate, give support to, and aid
regenerating cells and/or processes (e.g., axons), mimicking
crucial aspects of developmental path finding [102]. The cells
constitute the “living” component of scaffolds.
A very interesting study of Struzyna et al. [103] using
microtissue engineering neural networks for reconstituting
the architecture of axonal tracts demonstrates that this
approach is effective in promoting survival at least one
month and additionally they detected neurite penetration
and synapse formation [103]. In this referred study, the
microtube was constructed based on an agarose hydrogel
and the interior containing extracellular matrix proteins and
cerebral cortical neurons and was implanted in healthy rat
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brain. This very encouraging result presents a great potential
for neuroregenerative therapy and may ultimately facilitate
functional recovery if it could be transposed/overlapped in
stroke models in the future.
5. Biomaterials Degradation
Many materials formulated for tissue engineering and/or the
release of therapeutics are designed to be biodegradable (or
bioresorbable) to reduce the complications of tissue scarring
and glia tumor formation from permanent implants [70].
Thus, it is necessary to determine the biodegradability of
materials in vitro and in vivo [104]. Independent of their
composition (cross-linking reagents and the functional group
of HA derivatives), HA hydrogels have variable degradation
rate. By example, in Hahn et al., the authors demonstrated
that HA hydrogels prepared with three different cross-linking
reagents have variable degradation test results [105]. Indeed,
adipic acid dihydrazide grafted HA (HA-ADH), methacry-
lated HA (HA-MA), thiolated HA (HA-SH) were compared
and according to in vitro degradation tests, HA-SH hydrogel
was degraded very fast, compared to HA-ADH and HA-MA
hydrogels andHA-ADHhydrogel was degraded slightly faster
than HA-MA hydrogel. Moreover, when HA-MA hydrogels
and HA-SH hydrogels are implanted in the back of rats, HA-
SH hydrogel was in vivo degraded completely only in 2 weeks,
whereasHA-MAhydrogels were degraded only partially even
in 29 days.Therewas no adverse effect during the in vivo tests.
6. Biocompatibilities with Therapeutic Cells
and Host Tissue
Brain is mostly isolated from the periphery by the blood-
barrier. It has a similar but slightly different response to tissue
damage and foreign materials [70]. The use of biomaterials,
such as hydrogels, as neural cell delivery devices is becoming
more common in areas of research such as stroke, traumatic
brain injury, and spinal cord injury.
When reviewing the available research, there is some
ambiguity in the type ofmaterials used and results are often at
odds. Hydrogels must be designed to be biocompatible with
the implanted cells [106] and with the tissue environment. In
vitro cultures of embedded cells to assess cell compatibility
and functionality must be done prior to in vivo graft (Fig-
ure 1). 3D cultures can be useful to precise cell location and
cell distribution into a gel.
In vivo, a wide variety of synthetic polymers have been
shown to be biocompatible in the body, such as polyesters and
acrylates [107–110]. Natural polymers, such as poly(amino
acids) and HA, have been modified to form biocompatible
hydrogels. Polymeric hydrogels placed into a fimbria-fornix
lesion cavity promote fiber (re)growth in morphological
study in the rat [111–114]. This biocompatibility refers to
the histocompatibility of an implanted hydrogel and the
local and systemic response of the host which includes
the inflammatory and immune reaction of the brain [70].
Implanted biomaterials promote a foreign body response.
This inflammatory response presents a variable level which
varies depending on the material choice and the site of
implantation [115]. After implantation, a biomaterial acquires
a layer of host proteins that is associated with the surface
chemistry of material [58].
Brain tissue engineering in the postinjury brain repre-
sents a promising option for cell replacement and rescue,
providing a cell scaffold for transplanted or resident cells.
But a number of natural biomaterials have intrinsic anti-
inflammatory properties, including HA and chitosan [116].
Thus, they are suitable as carriers for anti-inflammatory
therapeutics. However, synthetic materials are also capable
of acting in an anti-inflammatory way. Zhong et al. have
demonstrated a beneficial effect of a hyaluronan-heparin-
collagen hydrogel by promoting the survival of ES-NPCs
and by reducing inflammatory infiltration of the graft with
the hydrogel transplant [11]. However, further optimization
of hydrogel compositions is warranted to avoid possible
inflammatory responses such as those observed in immuno-
competent mouse brain 2 weeks after IC injection of a HA
hydrogel preseeded with humanNSCs or glial precursors [8].
Indeed, HA degradation is facilitated in inflammation and
injury by the production of reactive oxygen and nitrogen
species [77, 117]. HA is degraded in vivo by hyaluronidases
(HAases) into shorter fragments. However, the extent of HA
degradation that occurs under pathological conditions may
be greatly enhanced.
7. Imaging of Biomaterials Engraftment
Clinical studies can benefit from noninvasive methods to
assess brain stroke. Experimental studies also have used
noninvasive imaging techniques to monitor grafted cells
distribution and their effects on brain tissue [118]. Several
imaging techniques such as MRI [31], positron emission
tomography (PET) [119], and nuclear imaging [9] have been
used to track transplanted cells in vivo. Imaging modalities
with precise anatomical information like MRI can be used to
evaluate the lesion size and extension and to precisely guide
biomaterial administration. Furthermore, recent advances
using multiparametric MRI enable longitudinal monitoring
of vascular remodeling [7, 120] and brain function by using
functional MRI.
Bible et al., for example, have demonstrated that NSCs
coadministrated with ECM bioscaffold produced from
porcine brain and urinary bladder promote the formation of
de novo tissue in the lesion cavity and repair processes after
ischemic stroke evaluated byMRI [121]. Noninvasive imaging
by MRI was used to guide the administration of biomaterials
in a similar study [97].
Noninvasive evaluations are a powerful tool for deter-
mining the efficacy of the combination biomaterials with
cell therapy, allowing a validation of biomaterial application
by a correlation of in vivo images and histological findings
(Figure 3).
8. Conclusion
The use of biomaterials for stroke therapy provides a promis-
ing avenue for cell transplantation, especially in the brain
where the regenerative properties can be limited.
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Figure 3: Representative images of in vivo and ex vivo detection of hyaluronan-acid (HA) hydrogel. (a)Magnetic Resonance Imaging (MRI)
weighed in T2, hydrogel detected at different time points (days one, seven, and fourteen after administration). (b) Cresyl violet staining of HA
hydrogel acquired two weeks after administration, noted in (×2) (b) and (c) (x10) magnification.These images demonstrate efficient local gel
formation instead of liquid diffusion which would be due to a delayed polymerization after infusion and the in vivo stability of HA hydrogel.
However, the choice of biomaterial compounds and prop-
erties must be adapted, according to biocompatibilities with
embedded cells and host tissue and to biodegradation rate.
Thus, collaborations between bioengineering researchers and
neuroscientists are required to validate and optimize preclin-
ical experiments. Purification of biomaterials is imperative
for safe use in humans.Therefore, it requires rigorous tests of
cytotoxicity. Important aspects such as reproducibility, corre-
lation with behavioral outcomes, and a long-term assessment
of biomaterials degradation should be considered before
clinical translation.
Hydrogels could be used to enhance cell transplantation
benefit in patients by stereotactic injection of liquid hydrogel
with in situ polymerization, or by surgical graft of stiffer cell-
biomaterial layers, for example, during a hemicraniectomy
for large stroke or during subsequent reparative cranioplasty.
An appropriate follow-up with a noninvasive brain imag-
ing to track hydrogel degradation and brain remodeling is
strongly indicated.
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